Verquvo Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Verquvo Indications
Indications
Verquvo Dosage and Administration
Adult
Children
Renal Impairment
No dosage adjustment is recommended in patients with eGFR ≥15mL/min/1.73m2 who are not on dialysis.
Verquvo has not been studied in patients with eGFR<15mL/min/1.73m2 at treatment initiation or on dialysis.
Hepatic Impairment
Mild or moderate hepatic impairment: No dosage adjustment is recommended.
Severe hepatic impairment: Not studied.
Other Modifications
Females of reproductive age: Use effective contraception during treatment and for at least 1 month after the final dose.
Verquvo Contraindications
Contraindications
Verquvo Boxed Warnings
Boxed Warning
Verquvo Warnings/Precautions
Warnings/Precautions
Verquvo Pharmacokinetics
Absorption
The absolute bioavailability of vericiguat is 93% when taken with food.
Results were comparable when Verquvo was administered orally as a whole tablet or as a crushed tablet in water.
Distribution
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
Elimination
Half-life of vericiguat is 30 hours.
Approximately 53% of the dose is excreted in urine and 45% in feces.
Verquvo Interactions
Interactions
Verquvo Adverse Reactions
Adverse Reactions
Verquvo Clinical Trials
Verquvo Note
Not Applicable
Verquvo Patient Counseling
Cost Savings Program
Images
